ATE404178T1 - Vorrichtung mit matrixgesteuerter wirkstofffreisetzung - Google Patents

Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Info

Publication number: ATE404178T1
Authority: AT; Austria
Prior art keywords: matrix; active release; controlled active; spray; dosage form
Prior art date: 1999-02-10

Application number

AT00300546T

Other languages

English (en)

Inventor

Leah Elizabeth Appel

Dwayne Thomas Friesen

William John Curatolo

James Alan Schrive Nightingale

Avinash Govind Thombre

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-10

Filing date

2000-01-26

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22384221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404178(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404178T1 publication Critical patent/ATE404178T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000002552 dosage form Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
238000013270 controlled release Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
239000007962 solid dispersion Substances 0.000 abstract 1
239000007921 spray Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Immunology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Nutrition Science (AREA)
Virology (AREA)
Vascular Medicine (AREA)

AT00300546T 1999-02-10 2000-01-26 Vorrichtung mit matrixgesteuerter wirkstofffreisetzung ATE404178T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11940099P	1999-02-10	1999-02-10

Publications (1)

Publication Number	Publication Date
ATE404178T1 true ATE404178T1 (de)	2008-08-15

Family

ID=22384221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00300546T ATE404178T1 (de)	1999-02-10	2000-01-26	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Country Status (7)

Country	Link
EP (1)	EP1027887B1 (de)
JP (2)	JP4355779B2 (de)
AT (1)	ATE404178T1 (de)
BR (1)	BR0000359A (de)
CA (1)	CA2298245C (de)
DE (1)	DE60039802D1 (de)
ES (1)	ES2310164T3 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000281561A (ja) *	1999-03-26	2000-10-10	Ajinomoto Co Inc	新規溶媒法固体分散体製剤
CN1402629A (zh) *	1999-12-23	2003-03-12	辉瑞产品公司	提供提高的药物浓度的药物组合物
US20010053791A1 (en) *	2000-03-16	2001-12-20	Babcock Walter C.	Glycogen phosphorylase inhibitor
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
KR20020014570A (ko) *	2000-08-18	2002-02-25	김충섭	고체분산화시킨 무정형 이프리플라본의 제조방법
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
EP1269994A3 (de)	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
OA12625A (en) *	2001-06-22	2006-06-12	Pfizer Prod Inc	Pharmaceutical compositions of adsorbates of amorphous drug.
JP2004534812A (ja)	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	薬物および中性ポリマーの分散物の医薬組成物
CA2450748A1 (en) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions containing polymer and drug assemblies
TNSN03137A1 (en)	2001-06-22	2005-12-23	Pfizer Prod Inc	PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
BR0210520A (pt)	2001-06-22	2004-06-22	Pfizer Prod Inc	Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
US7105178B2 (en)	2001-07-17	2006-09-12	Sun Pharmaceutical Industries Limited	Cardiotonic composition
EP1439824A2 (de) *	2001-10-29	2004-07-28	Therics, Inc.	Dreidimensionales suspensionsdrucken von darreichungsformen
EP1474123A1 (de) *	2002-01-03	2004-11-10	LEK Pharmaceuticals D.D.	Venlafaxin enthaltende pharmazeutische formulierung mit kontrollierter freisetzung
DE60320940D1 (de)	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2003063831A2 (en)	2002-02-01	2003-08-07	Pfizer Products Inc.	Immediate release dosage forms containing solid drug dispersions
BR0307515A (pt)	2002-02-01	2004-12-07	Pfizer Prod Inc	Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
PL372247A1 (en)	2002-02-01	2005-07-11	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CN1625397A (zh) *	2002-02-01	2005-06-08	辉瑞产品公司	胆固醇酯转移蛋白抑制剂的控制释放药物剂型
US6864373B2 (en) *	2002-05-13	2005-03-08	Pharmacia Corporation	Stable amorphous celecoxib composite and process therefor
SI21223A (sl) *	2002-06-19	2003-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
EP1530457B1 (de)	2002-08-12	2009-09-09	Bend Research, Inc.	Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
US7423004B2 (en)	2003-01-31	2008-09-09	Smithkline Beecham Corporation	Solid dispersion compositions
IL154370A0 (en) *	2003-02-10	2003-09-17	Chemagis Ltd	Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
DE10325989A1 (de) *	2003-06-07	2005-01-05	Glatt Gmbh	Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
BRPI0413277A (pt)	2003-08-04	2006-10-10	Pfizer Prod Inc	composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413363A (pt) *	2003-08-04	2006-10-10	Pfizer Prod Inc	formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
PE20142101A1 (es) *	2004-03-17	2014-12-27	Novartis Ag	Composiciones farmaceuticas de aliskiren
US20090142404A1 (en) *	2004-08-31	2009-06-04	Pfizer Inc	Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EP1789022A2 (de) *	2004-08-31	2007-05-30	Pfizer Products Incorporated	Kontrollierte dosierungsfreisetzungsformen, die die sofortige freisetzung und die verzögerte freisetzung eines arzneimittels mit geringer löslichkeit kombinieren
WO2006035433A2 (en)	2004-09-29	2006-04-06	Chemagis Ltd.	Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
MX2007007836A (es)	2004-12-27	2007-08-20	Eisai R&D Man Co Ltd	Metodo para estabilizar un farmaco anti-demencia.
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2594694A1 (en)	2005-01-28	2006-08-03	Pfizer Products Inc.	Drying of drug-containing particles
WO2006082500A1 (en) *	2005-02-03	2006-08-10	Pfizer Products Inc.	Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
CN101272767B (zh) *	2005-08-29	2012-08-29	赛诺菲-安万特美国有限责任公司	7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体
WO2008012617A1 (en)	2006-07-21	2008-01-31	Pfizer Products Inc.	Drying of drug-containing particles
PE20081506A1 (es)	2006-12-12	2008-12-09	Infinity Discovery Inc	Formulaciones de ansamicina
BRPI0807939A2 (pt) *	2007-04-03	2014-07-01	Reddys Lab Ltd Dr	Formas sólidas de pemetrexed
JP2010526848A (ja) *	2007-05-11	2010-08-05	エフ．ホフマン−ラロシュアーゲー	難溶性薬物用の医薬組成物
JP5048398B2 (ja) *	2007-06-13	2012-10-17	大蔵製薬株式会社	抗真菌剤の医薬組成物
SMT202000093T1 (it) *	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
US8329208B2 (en) *	2009-07-28	2012-12-11	Methylation Sciences International Srl	Pharmacokinetics of S-adenosylmethionine formulations
ES2414384T3 (es) *	2011-05-11	2013-07-19	Ratiopharm Gmbh	Composición de liberación modificada que comprende ranolazina
JO3339B1 (ar) *	2012-09-11	2019-03-13	Shanghai Inst Pharmaceutical Ind	شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
JP5877935B2 (ja)	2012-10-17	2016-03-08	メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎＳｃｉｅｎｃｅｓＩｎｔｅｒｎａｔｉｏｎａｌＳｒｌ	Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
JP5836980B2 (ja)	2013-01-11	2015-12-24	信越化学工業株式会社	薬物含有粒子、固形製剤及び薬物含有粒子の製造方法
EP3076951B1 (de) *	2013-12-05	2020-09-30	Celal Albayrak	Verfahren zur herstellung von arzneimittelformulierungen zur oralen verabreichung
AU2015257658A1 (en) *	2014-05-08	2016-11-10	Oncoethix Gmbh	Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
ES3063790T3 (en)	2015-06-09	2026-04-20	Lonza Sales Ag	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en)	2016-05-25	2016-07-06	F2G Ltd	Pharmaceutical formulation
US11819503B2 (en)	2019-04-23	2023-11-21	F2G Ltd	Method of treating coccidioides infection
CN113840595A (zh) *	2019-05-17	2021-12-24	葛兰素史密斯克莱知识产权发展有限公司	基质组合物，其包含(S)-5-苄基-N-(5-甲基-4-氧代-2,3,4,5-四氢苯并[b][1,4]氧氮杂环庚三烯-3-基)-4H-1,2,4-三唑-3-甲酰胺
JP7812785B2 (ja) *	2019-09-18	2026-02-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｙｋ２阻害薬の剤形
WO2024238657A2 (en)	2023-05-15	2024-11-21	Bonafide Health, Llc	Sleep-improving compositions and methods of use
AU2024344754A1 (en)	2023-09-21	2026-04-02	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2026033474A1 (en)	2024-08-08	2026-02-12	Takeda Pharmaceutical Company Limited	Deuterated compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649314A (en) *	1979-07-05	1981-05-02	Yamanouchi Pharmaceut Co Ltd	Lasting pharmaceutical composition having prolonged action and its preparation
JPS5948810B2 (ja) *	1980-03-22	1984-11-29	山之内製薬株式会社	ニカルジピン持続性製剤用組成物
JPS58116414A (ja) *	1981-12-23	1983-07-11	Yamanouchi Pharmaceut Co Ltd	ニカルジピン持続性製剤用球形顆粒およびその製造法
JP2528706B2 (ja) *	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	ジヒドロピリジン化合物の製剤組成物
TW212139B (de) *	1991-04-15	1993-09-01	Yamanouchi Pharma Co Ltd
IT1250654B (it) *	1991-07-08	1995-04-21	Farcon Ag	Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
JP2516524B2 (ja) *	1992-04-27	1996-07-24	大洋薬品工業株式会社	持続性製剤
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
HUT77530A (hu) *	1994-05-06	1998-05-28	Pfizer Inc.	Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
DE19515972A1 (de) *	1995-05-02	1996-11-07	Bayer Ag	Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
ES2287971T3 (es) *	1997-08-11	2007-12-16	Pfizer Products Inc.	Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.

2000
- 2000-01-26 AT AT00300546T patent/ATE404178T1/de not_active IP Right Cessation
- 2000-01-26 DE DE60039802T patent/DE60039802D1/de not_active Expired - Lifetime
- 2000-01-26 EP EP00300546A patent/EP1027887B1/de not_active Expired - Lifetime
- 2000-01-26 ES ES00300546T patent/ES2310164T3/es not_active Expired - Lifetime
- 2000-02-09 CA CA002298245A patent/CA2298245C/en not_active Expired - Lifetime
- 2000-02-10 BR BR0000359-0A patent/BR0000359A/pt not_active Application Discontinuation
- 2000-02-10 JP JP2000033446A patent/JP4355779B2/ja not_active Expired - Fee Related
2005
- 2005-08-04 JP JP2005226695A patent/JP4694298B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP4694298B2 (ja)	2011-06-08
BR0000359A (pt)	2001-08-14
JP2000229888A (ja)	2000-08-22
JP4355779B2 (ja)	2009-11-04
EP1027887A3 (de)	2001-02-28
EP1027887B1 (de)	2008-08-13
JP2005320354A (ja)	2005-11-17
CA2298245A1 (en)	2000-08-10
CA2298245C (en)	2004-11-30
DE60039802D1 (de)	2008-09-25
EP1027887A2 (de)	2000-08-16
ES2310164T3 (es)	2009-01-01

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE404178T1 (de)	2008-08-15	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ATE227120T1 (de)	2002-11-15	Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen
BR0000358A (pt)	2001-08-21	Liberação controlada por extrusão de dispersões amorfas sólidas de drogas
CY1109489T1 (el)	2014-08-13	Συσκευη χορηγησης φαρμακου
ES2144478T3 (es)	2000-06-16	Metodo y aparato para prevenir la opacificacion capsular posterior.
EE04216B1 (et)	2004-02-16	Vedel polümeerne kompositsioon ning selle kasutamine ravimina, mis on ette nähtud hüdrofoobse bioaktiivse aine reguleeritud vabastamiseks loomorganismis
ES2120543T3 (es)	1998-11-01	Dispositivo para la aplicacion de injertos.
DE69634009D1 (de)	2005-01-13	Implantierbare vorrichtung zur kontrollierten abgabe von arzneimitteln unmittelbar an einen inneren teil des körpers
DE69635734D1 (de)	2006-04-06	Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
DK1125577T3 (da)	2006-06-19	Væskeformige medikamentindföringspræparater
WO2001030323A3 (en)	2002-02-21	Controlled-release biocompatible ocular drug delivery implant devices and methods
BR9609663A (pt)	1999-05-18	Formulações para desprendimento controlado de medicamentos fracamente soluveis
ITMI922603A1 (it)	1994-05-13	Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
AU5673399A (en)	2000-03-14	Compositions and methods for treating intracellular infections
EP0873751A3 (de)	1998-12-23	Pharmazeutisches produkt zur anwendung auf der mukosa der gebärmutter
DE69831940D1 (de)	2006-03-02	Tablette mit verlängerter Wirkstoffabgabe im Magen
GEP20033078B (en)	2003-10-27	Controlled-Release Compositions of Betahistine
FR2757064B1 (fr)	2000-02-04	Lentille intraoculaire contenant un medicament relargable
ES2178631T3 (es)	2003-01-01	Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
DE60001717D1 (de)	2003-04-24	Mikrokapseln mit verzögerter freisetzung von wirkstoffen
CA2544460A1 (en)	2001-05-03	Controlled-release biocompatible ocular drug delivery implant devices and methods
HU9203420D0 (en)	1993-01-28	Biologically decomposable polymers for medical preparatives of delayed releqse of active agents
CA2269774A1 (en)	1998-05-07	Apparatus for preventing posterior capsular opacification